RIVENDELL GROUP LLP for GENENTECH
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to drug pricing, including H.R. 1520, the Purple Book Continuity Act; H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; issues related to Medicare and Medicaid coverage and reimbursement.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW LAWRENCE BERZOK | LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch |
| NICK KOLOVOS | LA and Counsel, Rep. Anna Eshoo |
Medicare/Medicaid MMM
Issues related to drug pricing, including H.R. 1520, the Purple Book Continuity Act; H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; issues related to Medicare and Medicaid coverage and reimbursement.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW LAWRENCE BERZOK | LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch |
| NICK KOLOVOS | LA and Counsel, Rep. Anna Eshoo |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.